
Dr. Ian Davis on 5-year enzalutamide survival data in mHSPC
Lead author Ian Davis, MBBS, PhD, discusses the results of the ENZAMET study update he shared during the 2022 ASCO Annual Meeting.
Ian D. Davis, MBBS, PhD, FRACP, FAChPM, of the Eastern Health Clinical School at Monash University in Box Hill, Australia, discusses results of the abstract, “Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC),” which he shared during the 2022 ASCO Annual Meeting (
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


















